Gilead Sciences Licenses Kymera Therapeutics’ Oral CDK2 Degrader KT-200 for Cancer Treatment

Kymera Therapeutics has announced that Gilead Sciences exercised its option to license KT-200, an oral CDK2 molecular glue degrader development candidate. This decision follows the terms outlined in a previously established collaboration agreement between the two companies. The licensing move grants Gilead exclusive rights to further develop and commercialize KT-200.

KT-200 is designed as a targeted therapeutic aimed at degrading cyclin-dependent kinase 2 (CDK2), which plays a role in cell cycle regulation and has been implicated in various cancers. Under the agreement, Kymera will receive an undisclosed payment from Gilead for exercising the option, along with potential milestone payments and royalties tied to future developments and sales of KT-200. The collaboration reflects ongoing efforts by both companies to advance innovative treatments in oncology and other disease areas.

Newsflash | Powered by GeneOnline AI

Source: GO-AI-ne1

For any suggestion and feedback, please contact us.

Date: April 9, 2026

Author

GOAI